what is a glp-1 drug made from receptor agonists New insights into nanomedicines for
Description
In 2012, a once-weekly version called Bydureon was approved
Adverse event reporting Adverse events were recorded as was drug compliance (unused medication in the injector pens documented)
2019;94(3):E7880
By joining Cureus, you agree to our Privacy Policy and Terms of Use.
The role of tumor necrosis factor-alpha in the pathogenesis and treatment of nonalcoholic fatty liver disease
Challenges: The key challenge for Sanofi is competition from more established and better marketed GLP-1 drugs, particularly those from Novo Nordisk and Eli Lilly
